The immuno-oncology therapy startup has completed a round that included New York Ventures and Taiho Pharmaceuticals.

US-based immuno-oncology drug developer Quentis Therapeutics has closed a $48m series A round featuring pharmaceutical companies AbbVie and Taiho, the former investing through its AbbVie Ventures unit. Venture capital firm Versant Ventures and investment firm Polaris Partners co-led the round along with LS Polaris Innovation Fund, an affiliate of the latter. The round also featured…

The rest of this content is only accessible to Global Government Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.